Clinical trial
Month 30 & 42 Extension Studies of CRD-004 Primary Study
NCT00492648 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00492648 |
|---|---|
| Title | Month 30 & 42 Extension Studies of CRD-004 Primary Study |
| Official title | An Extension Study to Evaluate the Persistence of the Immune Responses Induced by GSK Biologicals Zoster Vaccine, GSK324332A, Administered in Healthy Adult Subjects Aged 18-30 Years and 50-70 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Herpes Zoster |
| Intervention type | Procedure |
| Interventions | Blood sampling for assay of persistence of immunogenicity |
| Enrollment | 34 |
| Start date | Jun 25, 2007 |
| Primary completion | Jun 23, 2008 |
| Completion | Jun 23, 2008 |
| First posted | Jun 27, 2007 |
| Last update posted | Jun 26, 2019 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: